Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Hold” by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have been given an average recommendation of “Hold” by the ten ratings firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $8.4286.

Several analysts have recently issued reports on IOVA shares. Chardan Capital reduced their price objective on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Amtagvi sales drove a significant quarterly beat. Iovance reported Q2 product revenue of approximately $99.3 million, up 66% year over year and 39% from the prior quarter. U.S. Amtagvi revenue reached about $91 million, while adjusted EPS of $(0.11) was better than consensus estimates. Iovance Q2 earnings release
• Positive Sentiment: Profitability trends improved. Gross margin rose to 56% as higher sales volume, manufacturing efficiencies, and cost controls reduced pressure on the business. Management said margin improvement is expected to continue, and its cash position of approximately $304 million is expected to fund operations into the second half of 2028.
• Positive Sentiment: Pipeline and regulatory progress added potential upside. The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also looking ahead to additional melanoma and NSCLC data, including expected updates later this year and presentations at the ESMO meeting. A new early-stage IOV-5001 trial expands Iovance’s next-generation TIL pipeline.
• Positive Sentiment: Commercial expansion supports demand expectations. Iovance’s authorized treatment-center network exceeds 95 locations and is expected to reach at least 110 by year-end. Amtagvi has also received Australian approval, while U.K. regulatory review is ongoing.
• Neutral Sentiment: Buyout speculation contributed to the rally. Media reports cited growing acquisition buzz following the earnings beat, but no transaction has been announced, making this an unconfirmed potential catalyst. Buyout buzz report
• Negative Sentiment: Iovance remains unprofitable. The company posted a net loss of $47.3 million, with research and development expenses of $58.9 million. Management is reviewing its 2026 revenue outlook of $350 million to $370 million rather than raising it immediately, leaving some uncertainty about the pace of future growth.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock opened at $6.17 on Friday. Iovance Biotherapeutics has a 1 year low of $1.76 and a 1 year high of $6.39. The company has a market capitalization of $2.75 billion, a P/E ratio of -6.49 and a beta of 0.71. The business has a 50 day moving average price of $4.35 and a 200 day moving average price of $3.78.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $198.63 million for the quarter, compared to analysts’ expectations of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.Iovance Biotherapeutics’s quarterly revenue was up 65.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.33) EPS. As a group, research analysts expect that Iovance Biotherapeutics will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of IOVA. Arcataur Capital Management LLC acquired a new position in Iovance Biotherapeutics in the 4th quarter valued at $29,000. Granite Investment Partners LLC purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at $29,000. Motley Fool Asset Management LLC acquired a new position in Iovance Biotherapeutics in the fourth quarter valued at $29,000. M&T Bank Corp acquired a new position in Iovance Biotherapeutics in the fourth quarter valued at $31,000. Finally, SBI Securities Co. Ltd. lifted its position in Iovance Biotherapeutics by 169.1% during the fourth quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock worth $32,000 after buying an additional 7,269 shares during the period. Hedge funds and other institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.